The downgrade to Equal-Weight typically suggests that Wells Fargo believes Axonics is now valued appropriately, and investors should not expect significant outperformance compared to the market. However, the increase in the price target implies that there is still some optimism about the company's prospects, albeit less than before. This mixed signal may lead to a neutral short-term impact on the stock price as the market digests the news.